# Molecular and Cellular Immunology Core

> **NIH NIH P30** · UNIVERSITY OF HAWAII AT MANOA · 2022 · $193,526

## Abstract

Project Summary for the Molecular and Cellular Immunology Core 
As the singular research resource for flow cytometry, cell sorting and myriad immunological services at the 
University of Hawaii (UH) and in the entire State of Hawaii, the Molecular and Cellular Immunology (MCI) Core 
has had a significant impact on increasing research productivity, enhancing research competitiveness and 
heightening grants success during COBRE Phases I and II. Extramurally funded research is heavily dependent 
on the MCI Core, and the need is anticipated to grow during and beyond the Phase III COBRE period. 
The Phase III COBRE objective of facilitating the transition of the MCI Core into a sustainable state-of-the-art 
core facility capable of supporting high-caliber research on new, emerging and re-emerging infectious 
diseases, as well as other fields of scientific inquiry, will be achieved by (1) enhancing and streamlining core 
operations; (2) growing and diversifying the user base, capability, capacity and reach; and (3) strengthening 
the core infrastructure. For Aim 1, needs assessments and user satisfaction surveys will be conducted to 
ensure efficiency and effectiveness of core operations. Also, mentoring and training of current and prospective 
users will be better integrated, and partnerships will be formed with research training programs in infectious 
diseases and immunology. For Aim 2, outreach and marketing activities will be expanded to other local 
academic institutions, biotech companies and hospitals beyond the UH System, and strong partnerships will be 
formed with similar cores located in other COBRE, INBRE and IDeA-CTR programs to grow and diversify the 
core user base and to acquire new tools and techniques. Also, the MCI Core will leverage the existing 
infrastructure of research training laboratories in the Asia-Pacific region to facilitate international collaborative 
research. And for Aim 3, sustainability and phased-in business plans will be developed during the Phase III 
COBRE period to draw on multiple avenues of intramural and extramural support to sustain the Core. Periodic 
evaluation and review of the Core's fiscal health will allow necessary restructuring of the key elements affecting 
solvency to guide efforts to sustain the Core beyond Phase III COBRE support. 
The MCI Core is expected to achieve each of the above-stated specific aims. A strong commitment of $50,000 
per year for five years beyond the Phase III COBRE period, by the JABSOM Dean, will provide an important 
hedge against uncertain revenue streams during this competitive and uncertain funding climate and will ensure 
continued core operations, with the prospect of increased grants success and core sustainability.

## Key facts

- **NIH application ID:** 10576206
- **Project number:** 3P30GM114737-05S2
- **Recipient organization:** UNIVERSITY OF HAWAII AT MANOA
- **Principal Investigator:** George S Hui
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $193,526
- **Award type:** 3
- **Project period:** 2022-03-14 → 2023-07-13

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10576206

## Citation

> US National Institutes of Health, RePORTER application 10576206, Molecular and Cellular Immunology Core (3P30GM114737-05S2). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10576206. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*